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Hepatocellular carcinoma (HCC) is the fifth most common cancer globally, with an increasing incidence in many countries, and the second leading cause of cancer-re-lated mortality worldwide (1, 2). Among the various HCC treatment strategies, the 
Barcelona Clinic Liver Cancer (BCLC) staging system is the most preferred treatment guide-
line, because it not only allocates optimal treatment but helps to predict survival outcomes 
(3, 4). According to the BCLC guidelines, radiofrequency ablation (RFA) is recommended as 
the first-line treatment for patients with very early (0) or early (A) stage HCC. Prior studies 
have consistently demonstrated that RFA is comparable to surgical resection in terms of 
local tumor control rate for these patients (5, 6).
Other thermal ablation techniques have also been developed, and cryoablation in particular 
has been widely used in various other types of cancers including kidney, prostate, breast, and 
lung cancers (7). Compared with RFA, cryoablation has several advantages, including larger abla-
tive coverage, more discernible ablative margin, and less intraprocedural pain (8, 9). Furthermore, 
the advances in cryoablation technology such as thinner cryoprobes with newer argon-helium 
systems have made it possible to expand its applications to HCC. However, data on the clinical 
outcomes and safety of cryoablation for HCC are limited, and have been even more sparsely re-
ported in patients with HCC who are indicated for RFA under the BCLC guidelines.
The aim of this study was to evaluate the effectiveness and safety of percutaneous 
cryoablation (PC) for early or very early stage HCC lesions under the BCLC guidelines and to 
PURPOSE 
We aimed to evaluate the effectiveness and safety of percutaneous cryoablation (PC) for early 
or very early stage hepatocellular carcinoma (HCC) and assess the risk factors for local tumor 
progression (LTP) after PC.
METHODS
A total of 45 treatment-naïve patients treated with PC for early or very early stage HCCs were in-
cluded in this retrospective study. The safety of PC was assessed by evaluating procedure-related 
complications and comparing hepatic function before and after the procedure. The effectiveness 
was assessed by evaluating technical success, LTP rates, and disease progression (DP) rates. Prog-
nostic factors associated with LTP after PC were also analyzed.
RESULTS
Technical success and complete response were achieved in all patients (100%) by 1 month after 
PC. During a mean of 28.1±15.6 months of follow-up, the incidences of LTP and DP were 11.1% 
and 37.8%, respectively. The LTP-free and DP-free survival rates were 93.3% and 84.4% at 1 year 
and 88.9% and 62.2% at 2 years, respectively. Hepatic function was normalized within 3 months 
after PC. There were no major complications and only one minor complication of small hemato-
ma. On univariate and multivariate analysis, minimal ablative margin <5 mm was the only signif-
icant risk factor associated with LTP.
CONCLUSION
PC is a safe and effective therapy for patients with early or very early stage HCC. Minimal ablative 
margin <5 mm was a significant prognostic factor for LTP.
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This retrospective study was approved 
by our Institutional Review Board (4-2019-
0021), and the requirement for informed 
consent was waived. Between September 
2013 and December 2018, 199 patients 
underwent PC for HCC at our institution. 
The inclusion criteria for this study were 
patients with BCLC very early (0) or early (A) 
stage HCC. Patients who had history of pri-
or treatment for HCC, poor hepatic reserve 
(Child-Pugh score C), poor general condi-
tion (Eastern Cooperative Oncology Group 
Performance Status ≥2), evidence of extra-
hepatic metastasis or bleeding tendency 
(international normalized ratio [INR] of pro-
thrombin time [PT] ≥1.5 and platelet counts 
≤50000/μL) were excluded (10). Finally, a 
total of 45 patients (mean age, 61.0±12.2 
years; range, 46–79 years) were included in 
this study. Some of these patients were re-
ported in a previous work (11). 
HCC was diagnosed based on the typical 
imaging findings of liver dynamic comput-
ed tomography (CT) or magnetic resonance 
imaging (MRI) with elevated levels of serum 
α-fetoprotein (AFP) and/or prothrombin 
induced by vitamin K absence-II (PIVKA-II) 
(n=45) prior to PC. All patients in this study 
had underlying chronic liver disease or liver 
cirrhosis associated with hepatitis B (n=25), 
hepatitis C (n=4), nonviral hepatitis (n=7), 
or chronic alcoholism (n=9).
PC procedure
PC for HCC was performed in the hybrid 
angiography suite which was equipped 
with an angio-CT that incorporates a mul-
tidetector CT scanner (INFX-8000C com-
bined with Aquilion 128 channel CT scan-
ner, Toshiba Medical Systems Corp.) and 
angiography system. Thirty minutes before 
entering the procedural room, all patients 
were administered 25 mg of pethidine 
hydrochloride (Pethidine, Myungmoon 
Pharm) intramuscularly. After using 10–20 
mL of 1% lidocaine (Lidocaine, Daihan 
Pharm) for local anesthesia, the cryoprobes 
(IceRod i-Thaw 1.5 17 G straight cryoab-
lation probe, Gail Medical) were inserted 
into the tumor under ultrasonography (US) 
guidance (LOGIQ E9, General Electric). If the 
lesion was poorly visualized under US guid-
ance and thus difficult to target, CT and/
or fluoroscopy guidance was also utilized. 
After cryoprobe placement, unenhanced 
CT was used to determine if the lesion 
was appropriately targeted. The operators 
determined the number of cryoprobes, 
depending on the shape and size of the 
lesion, and at least two cryoprobes were 
inserted in a coaxial fashion to overlap the 
ablation zone. The mean distance between 
the cryoprobes used was 1.2±0.6 cm (range, 
0.7–1.8 cm) and it was close to 1.5 cm, the 
reported optimum distance between the 
17 G cryoprobes (12). The ablation pro-
cess consisted of a double-thaw cycle of a 
10-minute freezing period and 8-minute 
thawing period in each cycle (13). Between 
the first and second cycles, unenhanced 
CT was performed to monitor low-attenu-
ation ice-ball formation in maximum size. 
The field-of-view was set to cover the liver 
and adjacent organs with potential risks 
of procedure-related complications. After 
completion of PC, three-phase liver dynam-
ic contrast-enhanced CT was performed to 
evaluate if the ablation zone sufficiently 
covered the tumor and assess any immedi-
ate postprocedure complications.
Definitions and data analysis
Technical success was defined as the tu-
mor being completely within the cryoabla-
tion zone, as confirmed on CT immediately 
after PC. Local tumor progression (LTP) was 
defined as the appearance of new tumor 
foci at the ablative margin. Disease pro-
gression was defined as the emergence of 
intrahepatic distant recurrence, extrahe-
patic metastasis, or LTP (14). The degree of 
tumor necrosis was determined according 
to the modified response evaluation crite-
ria in solid tumor (mRECIST) (15). To obtain 
the minimal ablative margin (MAM), axial, 
coronal, and sagittal images of the pre- and 
post-ablation portal phase CT images were 
reviewed side by side but independently by 
two radiologists of 4 and 10 years of experi-
ence to compare the index tumor and the 
ablation zone. The distances from the edge 
of the tumor to the chosen anatomic land-
marks (e.g., liver surface, bone, and portal 
or hepatic vein) at three different sites on 
each axial, coronal, and sagittal image were 
measured on both pre- and postablation 
CT. The corresponding distances were sub-
tracted, and the shortest value was defined 
as the MAM (Fig. 1). Subcapsular lesion was 
defined as a lesion located within 1 cm from 
the liver surface (11).
Complications
Complications related to PC were divided 
into two categories: major and minor. Major 
complications were defined as events caus-
ing additional hospitalization or permanent 
adverse effects such as liver failure, severe 
thrombocytopenia, and cryoshock (mul-
tiorgan failure and disseminated intravas-
cular coagulation) (9, 16). All other events 
were defined as minor complications. 
Follow-up after initial cryoablation
For follow-up, patients underwent sched-
uled triple-phase contrast-enhanced CT 
1-month after initial PC and at 2- or 3-month 
intervals thereafter. Tumor markers (i.e., 
AFP and/or PIVKA-II) were also assessed at 
each follow-up. To evaluate changes in he-
patic function after PC, biochemical data 
including serum aspartate aminotransfer-
ase (AST), alanine aminotransferase (ALT), 
total bilirubin (TB), albumin levels, and the 
PT-INR were collected 1 day, 1 month, and 3 
months after the procedure.
Pain analysis
The visual analog scale (VAS) was used 
to evaluate pain during the procedure 
(17). Before the procedure, the VAS was ex-
plained to patients. Pain was evaluated be-
fore the procedure, after targeting, during 
cryoablation, and after completion of PC. 
Patients were also allowed to complain 
of pain at any time during the procedure. 
Among these, the most severe VAS value 
was recorded.
Statistical analysis
All statistical analyses were performed 
with SPSS 23.0 for Windows (IBM Corp). 
Data were tabulated as means and stan-
dard deviations for continuous variables 
and absolute numbers and percentages for 
categorical variables. Serum AST, ALT, TB, 
albumin levels, PT-INR, and AFP pre- and 
Main points
• Percutaneous cryoablation is an effective 
therapy for patients with early or very early 
stage hepatocellular carcinoma, which is 
comparable to radiofrequency ablation.
• Based on our study, percutaneous cryoabla-
tion could be a safe treatment modality for 
hepatocellular carcinoma with less pain and 
no major procedure-related complications.
• A minimal ablative margin <5 mm was a sig-
nificant prognostic factor for local tumor pro-
gression in percutaneous cryoablation.
postprocedure were compared using the 
paired sample t-test. Interobserver agree-
ment regarding the CT/MRI features, includ-
ing measurement of the MAM <5 mm and 
tumor size <2 cm, in each case was evaluat-
ed using kappa (κ) statistics. Kappa values 
were indicated as follows: less than 0.20, 
poor agreement; 0.21–0.40, fair agreement; 
0.41–0.60, moderate agreement; 0.61–0.80, 
good agreement; and greater than 0.81, 
excellent agreement (18). A univariate Cox 
proportional hazards model was used to 
elucidate predictors for LTP. Factors, sig-
nificantly associated with LTP (P < 0.1) in 
the univariate analysis, were included in 
the multivariate analysis. Outcomes were 
expressed as hazard ratios (HRs) and 95% 
confidence intervals (CIs). The P value of the 
model for Cox analysis was calculated by 
using likelihood ratio test. LTP-free survival 
(LTPFS), progression-free survival (PFS), and 
overall patient survival rates were calculat-
ed by using a Kaplan-Meier curve and com-
pared between groups by using a log-rank 
test. P values < 0.05 were considered statis-
tically significant.
Results
Patients were followed up for a range of 
7–68 months (mean, 28.1±15.6 months). 
The mean tumor size was 1.8±0.5 cm. 
Among 29 patients with hepatitis B or C, 
24 (82.8%) received antiviral medication 
during follow-up after PC. The patient and 
tumor characteristics are summarized in 
Table 1. 
The technical success rate was 100%. 
At 1 month imaging follow-up, complete 
response (CR) was achieved in all patients 
(100%). LTP occurred in 5 patients (11.1%), 
and disease progression, including LTP, 
occurred in 17 patients (37.8%) during fol-
low-up. In 5 patients with LTP (Fig. 2), addi-
tional PC was performed in 2 patients, RFA 
in 1 patient, and transarterial chemoembo-
lization (TACE) in 2 patients. Three patients 
who underwent PC or RFA showed no LTP. 
However, 2 patients who underwent TACE 
showed second LTP and had to receive re-
peat TACE. The LTPFS rates at 1 and 2 years 
were 93.3% (42/45) and 88.9% (40/45), 
respectively. The PFS rates at 1 year and 
2 years were 84.4% (38/45) and 62.2% 
(28/45), respectively. The median PFS was 
35 months (95% CI, 24.583–47.351) (Fig. 
3a, 3b) and the mean LTPFS was 24.6±16.1 
months. Overall survival rates at 1 year and 
2 years were 100% and 95.6% (43/45), re-
spectively. The LTP rates were significantly 
higher in patients with MAM <5 mm than 
those with MAM ≥5 mm (P = 0.018) on log-
rank test (Fig. 3c).
Kappa values (κ) of the tumor size, seg-
mental location, and MAM categorizations 
were 0.94 (P < 0.001), 0.87 (P = 0.002), and 
0.76 (P = 0.037), respectively. As shown in 
Table 2, independent risk factors associated 
with LTP were AFP ≥100 ng/mL and a MAM 
<5 mm on univariate Cox analysis. On mul-
tivariate Cox analysis, a MAM <5 mm was 
identified as the only statistically significant 
risk factor for LTP (P = 0.018).
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Figure 1. a–f. Minimal ablative margin (MAM) evaluation on each axial (a, b), coronal (c, d) and 
sagittal images (e, f) of computed tomography (CT). The shortest distance between pre-ablation CT 
(a, c, e) and post-ablation CT (b, d, f) is chosen at each plane and, among them, the shortest value of 
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Figure 2. a–f. A 75-year-old man with hepatocellular carcinoma (HCC) treated with percutaneous cryoablation (PC). Liver dynamic computed tomography 
(CT) images (a, b) demonstrated an enhancing mass with washout on portal phase in segment 6 measuring 2 cm (arrow), suggesting HCC. Follow-up CT 
images (c, d) obtained at 1 month after PC. The tumor was completely replaced by ablation zone (a), but its MAM was 3 mm, measured on axial plane. 





Figure 3. a–c. Kaplan-Meier curves of (a) local tumor progression (LTP)-free survival and (b) progression-free survival in patients who underwent 
percutaneous cryoablation for hepatocellular carcinoma. Log-rank test (c) shows significantly higher LTP rates in patients with a MAM <5 mm (P = 0.018).
a b c
The mean AFP levels were 85.7±193.6 
ng/mL before PC, which significantly de-
creased to 30.2 ng/mL (P = 0.023) and 
28.0 ng/mL (P = 0.040) 1 and 3 months 
after PC, respectively. The mean values of 
serum AST, ALT, TB, albumin, and PT-INR 
were 35.8 IU/L, 27.7 IU/L, 0.9 mg/dL, 3.9 g/
dL, and 1.1, respectively, before PC. One 
day after PC, the mean serum AST and ALT 
levels were significantly elevated to 241.4 
IU/L (P < 0.001) and 205.5 IU/L (P < 0.001), 
respectively. The mean TB levels were also 
significantly elevated to 1.1 mg/dL (P = 
0.001), but this was still within the normal 
limits. The mean serum albumin level was 
significantly decreased to 3.5 g/dL (P < 
0.001). One month after PC, serum AST, TB, 
and albumin levels had normalized to 35.0 
IU/L (P = 0.565), 0.8 mg/dL (P = 0.700), and 
4.0 g/dL (P = 0.238), respectively. The mean 
ALT level was significantly decreased to 
21.0 IU/L (P = 0.04) at 1 month, but normal-
ized to 28.3 IU/L (P = 0.881) at 3 months, 
showing no significant differences com-
pared with preprocedural levels. The mean 
value of PT-INR showed no significant dif-
ferences before and after PC (Fig. 4).
There were no major procedure-related 
complications. A small hematoma around 
the abdominal wall where the cryoprobes 
were placed was noted in one patient im-
mediately after PC, which was managed 
by conservative treatment. Two patients 
died during the follow-up period, but nei-
ther death was related to the procedure or 
HCC. The reasons for mortality included 
sepsis due to infective spondylitis and as-
piration pneumonia, respectively. During 
the procedure, pain was tolerable in all pa-
tients, with VAS ranging from 0 to 5 (mean, 
2.6±1.5). Ten patients required additional 
pain control: fentanyl (mean dosage, 
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Table 1. Characteristics of patients and lesions
Characteristics Value
Age (years), mean±SD 61.0±12.2
  <65 years 25 (55.6)
  ≥65 years 20 (44.4)
Sex (M:F), n 33:12
Etiology
  HBV 25 (55.6)
  HCV 4 (8.9)
  NBNC 7 (15.5)
  Alcoholic 9 (20.0)
Child-Pugh class
  A 41 (91.1)
  B 4 (8.9)
ECOG PS
  0 36 (80.0)
  1 9 (20.0)
Tumor number
  Solitary nodule 43 (95.6)
  Two or three nodules 2 (4.4)
Tumor size (cm), mean±SD 1.8±0.5
  <2 cm 28 (58.3)
  ≥2 cm 20 (41.7)
Minimal ablative margin (mm), mean±SD 6.3±1.8
  <5 mm 6 (12.5)
  ≥5 mm 42 (87.5)
AFP (ng/mL), mean±SD 85.7±193.6
  <100 34 (75.6)
  ≥100 11 (24.4)
Antiviral therapy during follow-up
  Yes 24 (82.8)
  No 5 (17.2)
Unless stated otherwise, values are presented as n (%).
M, male; F, female; HBV, hepatitis B virus; HCV, hepatitis C virus; NBNC, non-B non-C; ECOG PS, Eastern Cooperative 
Oncology Group Performance Status; AFP, α-fetoprotein. 
Figure 4. a–c. The mean values of collected biochemical data from the patients at 1 day before, and 1 day, 1 month, and 3 months after percutaneous 
cryoablation: (a), mean values of aspartate aminotransferase and alanine aminotransferase; (b), albumin; and (c), total bilirubin levels and prothrombin 
time international normalized ratio (PT-INR).
a b c
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39.3±13.3 μg) in 7 patients and pethidine 
(mean dosage, 16.6±6.7 mg) in 3 patients.
Discussion
Cryoablation is thought to have tumor-
icidal effects by extra- and intracellular ice 
formation, hypoxia induced by small vessel 
occlusion, cell dehydration and rupture, 
and promoting an immunologic response 
that suppresses tumor growth (19). With 
efficacy and safety profiles comparable to 
those of RFA, cryoablation may serve as a 
reliable alternative to RFA in the manage-
ment of early stage HCC (8). However, little 
data regarding the use of PC for early stage 
HCC exist. 
Many studies regarding the risk factors of 
LTP after RFA for HCC have been published, 
but there exist only a few such studies on 
PC for HCC (9, 20–22). Rong et al. (9) report-
ed that multiple lesions, tumor size >3 cm, 
and repeated ablation of the same lesions 
were independent risk factors associated 
with LTP after PC. However, MAM, known 
to be one of the most important risk factors 
associated with LTP after RFA, has not been 
evaluated in prior studies. In our study, the 
multivariate analysis demonstrated that 
a MAM <5 mm (P = 0.018) was the only 
significant risk factor for LTP after PC. This 
suggests that establishment of an at least 5 
mm ablative margin is effective in suppress-
ing LTP after PC of HCC, which is consistent 
with the findings from the previous studies 
of RFA (23, 24). Furthermore, contrary to PC, 
there were studies evaluating the effective-
ness and safety of RFA for subcapsular HCC 
with conflicting outcomes (25–27). Due to 
incomplete ablation and risk of thermal 
damage when performing ablation ther-
apy, subcapsular location could be a risk 
factor for local tumor recurrence. Howev-
er, in our study, subcapsular location was 
not associated with local tumor recurrence 
after PC (P = 0.832), in line with the recent 
studies on RFA. In a study by Lee et al. (28), 
to measure the maximal ablation capacity 
and minimize complications, the investiga-
tors performed PC with a single cryoprobe 
for solitary HCC lesions <3 cm in size. The 
CR rate in their study was significantly high-
er in patients with lesions ≤2 cm than in 
those with lesions with a diameter of 2–3 
cm (100% vs. 65%). In a large retrospec-
tive study, a single cryoprobe was used for 
lesions ≤2 cm, two cryoprobes for lesions 
>2 cm but ≤3.5 cm, and three cryoprobes 
for lesions >3.5 cm, and their CR rate was 
97.2% (9). In the present study, two or more 
cryoprobes were utilized in all patients, and 
the CR rate was 100%. This suggests that 
the ablation zone induced by a single cryo-
probe may not be sufficient in covering le-
sions measuring up to 3 cm in size. In addi-
tion, in vivo experiment is warranted to test 
the actual ablation coverage of a cryoprobe 
in relation to the varying degrees of under-
lying liver disease.
The CR rate of 100% in our study is not 
thought to be solely dependent on the 
use of multiple cryoprobes. It is assumed 
that the built-in CT scanner in the hybrid 
angio-CT unit helped to target the lesion 
accurately, and immediate post-ablation 
multi-phase contrast-enhanced CT allowed 
evaluation of the ablation zone and post-
procedural complications. If the tumor is 
not sufficiently replaced by the ablation 
zone, additional ablation can be performed, 
and if there are signs of bleeding along the 
ablation tract, emergency angiography can 
be immediately performed. Therefore, the 
angio-CT unit can serve as an adjunctive 
tool that makes PC safer and more effective.
Massive bleeding associated with paren-
chymal dehiscence along the cryoprobe 
trajectory and cryoshock syndrome are 
the two most devastating complications 
of cryoablation (29, 30). In our study, only 
one (2.2%) minor complication occurred. 
The use of thinner (17 G) cryoprobes may 
explain the lack of parenchymal dehiscence 
and massive bleeding. Cryoshock is known 
to develop in up to 1% of liver ablations, 
and may be attributed to necrotic debris 
flowing directly into the bloodstream 
during the procedure (31, 32). As freezing 
30% to 35% of the liver volume is associated 
with cryoshock syndrome (33), PC for large 
lesions carries a higher risk for this severe 
systemic adverse event. Therefore, small 
and early lesions, e.g., BCLC 0 or A category, 
seem to be better candidates for PC.
As severe pain is not uncommon in RFA 
even with conscious sedation, general an-
esthesia is sometimes or routinely required. 
In a study by Lee et al. (34), the mean pro-
cedural VAS score was 5.53 in patients un-
dergoing RFA. Cryoablation is reported to 
be less painful in the treatment of nonliver 
tumors, and hence a lower dose of seda-
tives and narcotic analgesics needs to be 
administered (35, 36). In our patients who 
underwent PC without sedation, the mean 
VAS score was 2.6±1.5 (range, 0–5), and ad-
ditional pain medication was required in 10 
patients (22.2%). This obviates the need for 
conscious sedation or general anesthesia, 
and thus PC can be more safely performed 
than other percutaneous ablative treat-
ment in HCC patients.
In recent years, microwave ablation 
(MWA), one of the thermal ablative thera-
pies, has also been used to treat HCC, show-
ing clinical outcomes comparable to RFA. 
However, there have been procedure-relat-
ed complications on thermal ablative ther-
apies, with major complication rates 4.1% 
for RFA and 4.6% for MWA, respectively, 
and the overall incidence of gastrointesti-
nal track perforation was reported in about 
0.1%–0.3% (37). Furthermore, microwave 
Table 2. Univariate and multivariate Cox analyses for predictors of LTP
Variables
Univariate analysis Multivariate analysis*
HR 95% CI P Adjusted HR 95% CI P
AFP ≥100 ng/mL 17.305 3.445–33.988 0.004 13.783 2.425–53.339 0.078
Subcapsular location 1.237 0.778–3.261 0.832
Tumor multiplicity 1.889 1.185–15.364 0.525
Size ≥2 cm 2.108 0.263–17.062 0.456
MAM <5 mm 24.391 2.043–79.317 0.001 23.877 1.808–274.210 0.018
LTP, local tumor progression; HR, hazard ratio; CI, confidence interval; OR, odds ratio; AFP, α-fetoprotein, MAM, minimal ablative margin.
*The P value of the model for Cox analysis (likelihood ratio test P value) < 0.001.
could cause severe pain during the proce-
dure, which possibly interferes with com-
plete ablation. In contrast, PC causes less 
pain and thus patients are usually stable 
during the procedure (16). Compared with 
MWA, PC may be more expensive in some 
regions, but it has advantages in terms of 
less procedure-related major complications 
and less pain. However, long-term oncolog-
ic outcomes should be evaluated and com-
pared in a future study.
There were some limitations in our study. 
First, it was a retrospective study, and selec-
tion bias could affect the results. Second, 
the MAM was determined by measuring 
distances between two landmarks manually 
on each axial, coronal, and sagittal image on 
both pre- and postablation CT. Though the κ 
value for the MAM <5 mm was good (0.76), 
it could be inaccurate because the distances 
were measured by free-hand drawing. Third, 
our population was relatively small, and the 
follow-up intervals were relatively short. 
Long-term outcomes should be further in-
vestigated. However, the short-term out-
comes we describe are in line with previous 
reports, as mentioned above. Finally, we did 
not have a control group. 
In conclusion, PC is a safe and effective 
ablative treatment modality for early or very 
early stage HCC. Moreover, a MAM <5 mm 
was a significant prognostic factor for LTP.  
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